Canada: The Year In Review: 2014 Highlights In Canadian Pharmaceutical IP And Regulatory News

The following are highlights of developments in Canadian pharmaceutical intellectual property and regulatory law in 2014.

1. Health Canada approves first antibody SEBs

On January 15, Health Canada approved Celltrion's REMSIMA and INFLECTRA (NOC now in the name of Hospira), each containing the monoclonal antibody, infliximab. They were filed as subsequent entry biologics to Janssen's REMICADE and did not receive approval for all of its indications.

2. Court of Appeal issues first section 8 quantification decisions (ramipril); Supreme Court grants sanofi-aventis leave

On March 14, the Federal Court of Appeal reversed in part the first two decisions quantifying section 8 damages, employing different hypothetical models from that of the trial judge. The cases relate to ramipril (sanofi-aventis' ALTACE, Apo-Ramipril and Teva-Ramipril). The Supreme Court subsequently granted sanofi-aventis leave to appeal the Apotex decision.

3. Federal Court finds PMPRB does not have jurisdiction over ratiopharm and Sandoz

On May 27, the Federal Court decided that ratiopharm (selling an authorized generic version of VENTOLIN HFA) and Sandoz, a subsidiary of the patentee Novartis, are not "patentees" and are therefore not subject to the Board's pricing jurisdiction. The PMPRB has appealed.

4. Heightened matching requirement for patent listing; Regulations to be amended

On September 18, the Federal Court upheld a Prothonotary's finding that a patent explicitly claiming one medicinal ingredient was not eligible for listing on the Patent Register against the fixed-dose combination products KIVEXA and TRIZIVIR. Viiv has appealed. Industry Canada will be amending the Patented Medicines (Notice of Compliance) Regulations.

5. Competition Bureau releases white paper on patent litigation settlements

On September 23, the Competition Bureau released a white paper providing the Bureau's preliminary views on how the Competition Act may apply to both entry-date settlements (limited to generic entry prior to patent expiry) and "pay-for-delay" agreements.

6. CETA: Text released, patent term restoration coming to Canada

On September 26, the text of CETA (the Comprehensive Economic and Trade Agreement between Canada and Europe) was released and includes patent term restoration and an innovator right of appeal under the Patented Medicines (Notice of Compliance) Regulations. The agreement must still be ratified and domestic laws amended.

7. Health Canada imposes import ban on products from sites in India; Apotex sues

On September 30, Health Canada commenced action to stop the import of health products from Apotex Pharmachem India Pvt Ltd (APIPL), Apotex Research Private Limited (ARPL), and IPCA Laboratories (the Department in India), noting "serious doubts about the quality and safety of finished products and APIs produced at these sites." Apotex brought applications challenging this decision (T-2223-14) and Health Canada's decision refusing a NOC for Apo-Rasagiline stemming from this import ban (T-2411-14).

8. Court of Appeal permits Janssen to amend its plea, dissolves STELARA injunction and orders new trial

On October 28, the Federal Court of Appeal granted Janssen's appeal of a pre-trial Order denying its request to plead further prior art references, consequently set aside the lower Court's decision declaring Abbvie's patent valid and infringed by Janssen's antibody drug STELARA (ustekinumab), and remitted the matter back for a new trial before a new judge. The injunction was also set aside. The new trial has been scheduled for January 2016. Abbvie has sought leave to appeal from the Supreme Court.

9. Utility: Apotex discontinues PLAVIX appeal on eve of SCC hearing

On November 3, Apotex discontinued its appeal to the Supreme Court of Canada regarding the validity of sanofi-aventis' patent claiming clopidogrel bisulfate (PLAVIX). Had the appeal proceeded, the Supreme Court was expected to provide guidance on Canada's "promise" doctrine of utility and the test for sound prediction of utility.

Separately, on October 30, the Federal Court of Appeal provided further clarity regarding the "promise" doctrine, upholding prohibition Orders regarding celecoxib (Pfizer's CELEBREX).

10. CHEO challenges validity of gene patents

On November 3, the Children's Hospital of Eastern Ontario ("CHEO") brought a Claim seeking a declaration of invalidity and non-infringement of five Canadian patents relating to nucleotide and amino acid sequences of genes and proteins implicated in Long QT syndrome ("Long QT"), an inherited cardiac disorder.

11. Vanessa's Law: Health Canada has heightened powers to address adverse drug reporting

On November 6, the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) received royal assent. The Act strengthens oversight of drugs, devices and drug-device combinations post-approval, and provides Health Canada with new powers to compel and disclose information, order changes to labels and packages and recall products that present serious or imminent risk of injury to health.

12. Health Canada found negligent in handling of Apo-Trazodone regulatory submission

On November 18, the Federal Court found the Minister of Health liable to pay damages to Apotex for misfeasance in public office and negligence for its failure to abide by a settlement agreement relating to use of a foreign reference product, which delayed the approval of Apotex's generic trazodone product. The Queen has appealed.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Smart & Biggar/Fetherstonhaugh
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Smart & Biggar/Fetherstonhaugh
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions